<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04799925</url>
  </required_header>
  <id_info>
    <org_study_id>Diabetic Nephropathy Uric Acid</org_study_id>
    <nct_id>NCT04799925</nct_id>
  </id_info>
  <brief_title>Hyperuricemia and Diabetic Nephropathy</brief_title>
  <official_title>Effect of Treatment of Hyperuricemia on Progression of Diabetic Nephropathy in Patients With Type II Diabetes Mellitus and Stage III Chronic Kidney Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to detect the effect of treatment of hyperuricemia on eGFR&#xD;
      (Estimated Glomerular Filtration Rate) as an objective criterion for assessment of&#xD;
      progression of diabetic nephropathy in patients with Type 2 Diabetes Mellitus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all patients giving written&#xD;
      informed consent will undergo a 1-week screening period to determine eligibility for study&#xD;
      entry.&#xD;
&#xD;
      At week 0, patients who meet the eligibility requirements will be randomized in a&#xD;
      double-blind manner (participant and investigator) in a 1:1 ratio to Febuxostat (80 mg, once&#xD;
      daily) or Placebo (once daily) in patients with Type 2 Diabetes Mellitus and Stage 3 Chronic&#xD;
      Kidney Disease (Estimated Glomerular Filtration Rate 31:59).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of treatment of hyperuricemia on estimated Glomerular Filtration Rate by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.</measure>
    <time_frame>6 months from September 2021 to march 2022.</time_frame>
    <description>Number of Participants with type 2 Diabetes Mellitus and stage 3 Chronic Kidney Disease (eGFR: 31:59) will be treated with uric acid lowering drug (febuxostat, 80 mg, once daily) for 6 months to detect the effect of treatment of hyperuricemia on estimated Glomerular Filtration Rate by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hyperuricemia</condition>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <description>Hyperuricemic group will be treated with uric acid lowering drug (febuxostat 80 mg once daily for 6 months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <description>Hyperuricemic group will take placebo pills.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>uric acid lowering agent. dose: 80 mg once daily. duration: for 6 months</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient population will include both males and females above the age of 18 years with T2DM&#xD;
        and Diabetic Nephropathy stage 3 CKD (eGFR: 31-59).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient population will include both males and females above the age of 18 years with&#xD;
             T2DM and Diabetic Nephropathy stage 3 CKD (eGFR: 31-59).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with history of hypothyroidism, alcoholism, urinary tract infections,&#xD;
             glomerulonephritis, myeloproliferative disorders and gout &quot;as gout is a common&#xD;
             inflammatory arthropathy characterized by painful and swollen joints resulting from&#xD;
             precipitating uric acid crystals but hyperuricemia is commonly asymptomatic&quot; or on&#xD;
             drugs capable of inducing Hyperuricemia will be excluded from the study.&#xD;
&#xD;
          -  Any patient will develop acute kidney injury episode at any time of the study will be&#xD;
             excluded from the study.&#xD;
&#xD;
          -  Patients with uncontrolled hypertension will be excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mohamed Ragab Eldremi</last_name>
    <phone>00201114430050</phone>
    <email>muhammadragab90@gmail.com</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>mohammad ragab eldremi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 20, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT04799925/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

